Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC)

A novel AT2R agonist effectively attenuates growth of PDAC grafts in mice

Susumu Ishiguro, Kiyoshi Yoshimura, Ryouichi Tsunedomi, Masaaki Oka, Sonshin Takao, Makoto Inui, Atsushi Kawabata, Terrahn Wall, Vassiliki Magafa, Paul Cordopatis, Andreas G. Tzakos, Masaaki Tamura

Research output: Contribution to journalArticle

Abstract

We have recently discovered the potential involvement of angiotensin II type 2 receptor (AT2R) signaling in pancreatic cancer using AT2R deficient mice. To examine the involvement of AT2R expression in human PDAC, expressions of AT2R as well as the major angiotensin II receptor (type 1 receptor, AT1R) in human PDAC and adjacent normal tissue was evaluated by immunohistochemistry and real time PCR using surgically dissected human PDAC specimens. In immunohistochemical analysis, relatively strong AT1R expression was detected consistently in both normal pancreas and PDAC areas, whereas moderate AT2R expression was detected in 78.5% of PDAC specimens and 100% of normal area of the pancreas. AT1R, but not AT2R, mRNA levels were significantly higher in the PDAC area than in the normal pancreas. AT2R mRNA levels showed a negative correlation trend with overall survival. In cell cultures, treatment with a novel AT2R agonist significantly attenuated both murine and human PDAC cell growth with negligible cytotoxicity in normal epithelial cells. In a mouse study, administrations of the AT2R agonist in tumor surrounding connective tissue markedly attenuated growth of only AT2R expressing PAN02 murine PDAC grafts in syngeneic mice. The AT2R agonist treatment induced apoptosis primarily in tumor cells but not in stromal cells. Taken together, our findings offer clinical and preclinical evidence for the involvement of AT2R signaling in PDAC development and pinpoint that the novel AT2R agonist could serve as an effective therapeutic for PDAC treatment.

Original languageEnglish (US)
Pages (from-to)307-316
Number of pages10
JournalCancer Biology and Therapy
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Angiotensin Type 2 Receptor
Adenocarcinoma
Transplants
Growth
Pancreas
Messenger RNA
Angiotensin Type 1 Receptor
Therapeutics
Stromal Cells
Pancreatic Neoplasms
Connective Tissue

Keywords

  • Angiotensin II type 2 receptor (AT2R)
  • Apoptosis
  • Pancreatic ductal adenocarcinoma
  • Selective AT2R agonist

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC) : A novel AT2R agonist effectively attenuates growth of PDAC grafts in mice. / Ishiguro, Susumu; Yoshimura, Kiyoshi; Tsunedomi, Ryouichi; Oka, Masaaki; Takao, Sonshin; Inui, Makoto; Kawabata, Atsushi; Wall, Terrahn; Magafa, Vassiliki; Cordopatis, Paul; Tzakos, Andreas G.; Tamura, Masaaki.

In: Cancer Biology and Therapy, Vol. 16, No. 2, 01.02.2015, p. 307-316.

Research output: Contribution to journalArticle

Ishiguro, S, Yoshimura, K, Tsunedomi, R, Oka, M, Takao, S, Inui, M, Kawabata, A, Wall, T, Magafa, V, Cordopatis, P, Tzakos, AG & Tamura, M 2015, 'Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): A novel AT2R agonist effectively attenuates growth of PDAC grafts in mice', Cancer Biology and Therapy, vol. 16, no. 2, pp. 307-316. https://doi.org/10.1080/15384047.2014.1002357
Ishiguro, Susumu ; Yoshimura, Kiyoshi ; Tsunedomi, Ryouichi ; Oka, Masaaki ; Takao, Sonshin ; Inui, Makoto ; Kawabata, Atsushi ; Wall, Terrahn ; Magafa, Vassiliki ; Cordopatis, Paul ; Tzakos, Andreas G. ; Tamura, Masaaki. / Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC) : A novel AT2R agonist effectively attenuates growth of PDAC grafts in mice. In: Cancer Biology and Therapy. 2015 ; Vol. 16, No. 2. pp. 307-316.
@article{ef727b9a307846da9864e88a8d40908c,
title = "Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): A novel AT2R agonist effectively attenuates growth of PDAC grafts in mice",
abstract = "We have recently discovered the potential involvement of angiotensin II type 2 receptor (AT2R) signaling in pancreatic cancer using AT2R deficient mice. To examine the involvement of AT2R expression in human PDAC, expressions of AT2R as well as the major angiotensin II receptor (type 1 receptor, AT1R) in human PDAC and adjacent normal tissue was evaluated by immunohistochemistry and real time PCR using surgically dissected human PDAC specimens. In immunohistochemical analysis, relatively strong AT1R expression was detected consistently in both normal pancreas and PDAC areas, whereas moderate AT2R expression was detected in 78.5{\%} of PDAC specimens and 100{\%} of normal area of the pancreas. AT1R, but not AT2R, mRNA levels were significantly higher in the PDAC area than in the normal pancreas. AT2R mRNA levels showed a negative correlation trend with overall survival. In cell cultures, treatment with a novel AT2R agonist significantly attenuated both murine and human PDAC cell growth with negligible cytotoxicity in normal epithelial cells. In a mouse study, administrations of the AT2R agonist in tumor surrounding connective tissue markedly attenuated growth of only AT2R expressing PAN02 murine PDAC grafts in syngeneic mice. The AT2R agonist treatment induced apoptosis primarily in tumor cells but not in stromal cells. Taken together, our findings offer clinical and preclinical evidence for the involvement of AT2R signaling in PDAC development and pinpoint that the novel AT2R agonist could serve as an effective therapeutic for PDAC treatment.",
keywords = "Angiotensin II type 2 receptor (AT2R), Apoptosis, Pancreatic ductal adenocarcinoma, Selective AT2R agonist",
author = "Susumu Ishiguro and Kiyoshi Yoshimura and Ryouichi Tsunedomi and Masaaki Oka and Sonshin Takao and Makoto Inui and Atsushi Kawabata and Terrahn Wall and Vassiliki Magafa and Paul Cordopatis and Tzakos, {Andreas G.} and Masaaki Tamura",
year = "2015",
month = "2",
day = "1",
doi = "10.1080/15384047.2014.1002357",
language = "English (US)",
volume = "16",
pages = "307--316",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC)

T2 - A novel AT2R agonist effectively attenuates growth of PDAC grafts in mice

AU - Ishiguro, Susumu

AU - Yoshimura, Kiyoshi

AU - Tsunedomi, Ryouichi

AU - Oka, Masaaki

AU - Takao, Sonshin

AU - Inui, Makoto

AU - Kawabata, Atsushi

AU - Wall, Terrahn

AU - Magafa, Vassiliki

AU - Cordopatis, Paul

AU - Tzakos, Andreas G.

AU - Tamura, Masaaki

PY - 2015/2/1

Y1 - 2015/2/1

N2 - We have recently discovered the potential involvement of angiotensin II type 2 receptor (AT2R) signaling in pancreatic cancer using AT2R deficient mice. To examine the involvement of AT2R expression in human PDAC, expressions of AT2R as well as the major angiotensin II receptor (type 1 receptor, AT1R) in human PDAC and adjacent normal tissue was evaluated by immunohistochemistry and real time PCR using surgically dissected human PDAC specimens. In immunohistochemical analysis, relatively strong AT1R expression was detected consistently in both normal pancreas and PDAC areas, whereas moderate AT2R expression was detected in 78.5% of PDAC specimens and 100% of normal area of the pancreas. AT1R, but not AT2R, mRNA levels were significantly higher in the PDAC area than in the normal pancreas. AT2R mRNA levels showed a negative correlation trend with overall survival. In cell cultures, treatment with a novel AT2R agonist significantly attenuated both murine and human PDAC cell growth with negligible cytotoxicity in normal epithelial cells. In a mouse study, administrations of the AT2R agonist in tumor surrounding connective tissue markedly attenuated growth of only AT2R expressing PAN02 murine PDAC grafts in syngeneic mice. The AT2R agonist treatment induced apoptosis primarily in tumor cells but not in stromal cells. Taken together, our findings offer clinical and preclinical evidence for the involvement of AT2R signaling in PDAC development and pinpoint that the novel AT2R agonist could serve as an effective therapeutic for PDAC treatment.

AB - We have recently discovered the potential involvement of angiotensin II type 2 receptor (AT2R) signaling in pancreatic cancer using AT2R deficient mice. To examine the involvement of AT2R expression in human PDAC, expressions of AT2R as well as the major angiotensin II receptor (type 1 receptor, AT1R) in human PDAC and adjacent normal tissue was evaluated by immunohistochemistry and real time PCR using surgically dissected human PDAC specimens. In immunohistochemical analysis, relatively strong AT1R expression was detected consistently in both normal pancreas and PDAC areas, whereas moderate AT2R expression was detected in 78.5% of PDAC specimens and 100% of normal area of the pancreas. AT1R, but not AT2R, mRNA levels were significantly higher in the PDAC area than in the normal pancreas. AT2R mRNA levels showed a negative correlation trend with overall survival. In cell cultures, treatment with a novel AT2R agonist significantly attenuated both murine and human PDAC cell growth with negligible cytotoxicity in normal epithelial cells. In a mouse study, administrations of the AT2R agonist in tumor surrounding connective tissue markedly attenuated growth of only AT2R expressing PAN02 murine PDAC grafts in syngeneic mice. The AT2R agonist treatment induced apoptosis primarily in tumor cells but not in stromal cells. Taken together, our findings offer clinical and preclinical evidence for the involvement of AT2R signaling in PDAC development and pinpoint that the novel AT2R agonist could serve as an effective therapeutic for PDAC treatment.

KW - Angiotensin II type 2 receptor (AT2R)

KW - Apoptosis

KW - Pancreatic ductal adenocarcinoma

KW - Selective AT2R agonist

UR - http://www.scopus.com/inward/record.url?scp=84924533040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924533040&partnerID=8YFLogxK

U2 - 10.1080/15384047.2014.1002357

DO - 10.1080/15384047.2014.1002357

M3 - Article

VL - 16

SP - 307

EP - 316

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 2

ER -